Welcome to our dedicated page for Xenon Pharmaceut news (Ticker: XENE), a resource for investors and traders seeking the latest updates and insights on Xenon Pharmaceut stock.
Xenon Pharmaceuticals Inc. reports news on its neuroscience-focused biopharmaceutical pipeline, including drug discovery, clinical development and commercialization plans for neurological and psychiatric disorders. The company’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 clinical development for epilepsy, major depressive disorder and bipolar depression.
Recurring updates include azetukalner clinical data in focal onset seizures, presentations at medical and investor conferences, financial results, business updates, public offerings, inducement equity grants and early-stage potassium and sodium channel programs, including KV7 and NaV1.7 candidates being developed for pain.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) will report its 2020 financial results on March 1, 2021, after U.S. market close. A conference call and webcast will follow at 4:30 PM ET to discuss these results and provide a corporate update. Additionally, Xenon will participate in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 10:00 AM ET, which will be webcast live.
Xenon is focused on developing innovative therapeutics for neurological disorders, particularly epilepsy.
Xenon Pharmaceuticals (XENE) presented promising pre-clinical and clinical data on XEN1101, a Kv7 potassium channel modulator, at ASENT 2021. The ongoing Phase 2b X-TOLE clinical trial shows XEN1101 is effective as adjunctive treatment for adult patients with focal epilepsy, with results expected in Q3 2021. New data suggest potential efficacy for mood disorders like depression and anhedonia. Initial results indicate XEN1101 may be well-tolerated, with positive pre-clinical evidence supporting its use in combinations with other medications.
Xenon Pharmaceuticals announces a leadership transition planned for June 2021, with Simon Pimstone stepping down as CEO to become Executive Chair, while Ian Mortimer will take over as CEO. The company anticipates key milestones in 2021, including topline data from the XEN1101 Phase 2b X-TOLE trial for adult focal epilepsy, expected in Q3 2021, and the initiation of the Phase 3 EPIK trial for XEN496 in pediatric KCNQ2-DEE. The press release highlights the company's commitment to developing innovative treatments for neurological disorders.
Xenon Pharmaceuticals announced promising interim data on XEN007 from a Phase 2 study for treating Childhood Absence Epilepsy (CAE). All three patients demonstrated over a 50% reduction in seizures, with two achieving over 80% reduction. The study is well tolerated with no serious adverse events reported. Future enrollment will focus solely on CAE, given these favorable results. Xenon continues to advance its pipeline, including XEN1101 and XEN496, with presentations scheduled at AES2020.
Xenon Pharmaceuticals Inc. (Nasdaq:XENE) announced that CEO Dr. Simon Pimstone will participate in key virtual investor conferences. These include:
- Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on November 16, 2020.
- Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 4:40 pm ET.
- Jefferies Virtual London Healthcare Conference on November 19, 2020, at 9:40 am ET (2:40 pm GMT).
Details and webcasts will be available on the company website following the events.
Xenon Pharmaceuticals (Nasdaq:XENE) reported third quarter 2020 financial results, highlighting a total revenue of $6.6 million, up from $3.5 million in Q3 2019. Cash reserves stand at approximately $191 million, extending their cash runway into 2023. The company is progressing with its XEN1101 Phase 2b and XEN496 Phase 3 clinical trials, despite COVID-19 challenges. Additionally, Patrick Machado was appointed to the Board of Directors, bringing over 20 years of biotech experience. Topline data for the X-TOLE trial is now expected in Q3 2021.
Xenon Pharmaceuticals (Nasdaq:XENE) announced it will release its Q3 2020 financial and operating results after U.S. markets close on November 5, 2020. Management will host a conference call and live webcast at 4:30 PM ET to discuss results and provide a corporate update. Investors can participate by calling (855) 779-9075 or (631) 485-4866 for international access, using conference ID 8125409. The event will be accessible on Xenon’s website and available for replay for 30 days.
Xenon Pharmaceuticals announced a positive opinion from the European Medicines Agency's COMP for orphan medicinal product designation for XEN496, aimed at treating KCNQ2 DEE. The FDA has also granted Fast Track designation for XEN496, with plans to initiate a Phase 3 clinical trial in pediatric patients by year-end. The trial will evaluate the efficacy and safety of XEN496 in approximately 40 pediatric patients. This milestone underscores the seriousness of KCNQ2-DEE and validates Xenon's precision medicine approach.
The FDA has requested additional non-clinical data from Neurocrine Biosciences to support the dose justification for NBI-921352 in a Phase II trial for pediatric SCN8A-DEE patients. This request follows the granting of Rare Pediatric Disease Designation for NBI-921352, which targets a rare pediatric epilepsy. Neurocrine and Xenon Pharmaceuticals are collaborating on this project and aim to initiate the trial in 2021, while also advancing plans for adult focal epilepsy treatment.
Xenon Pharmaceuticals (Nasdaq: XENE) announced the appointment of Dr. Chris Von Seggern as Chief Commercial Officer, effective immediately. Dr. Von Seggern will lead the company's commercial strategy for its neurology-focused therapeutics. Dr. Simon Pimstone, CEO, praised Dr. Von Seggern's extensive experience in orphan diseases and successful drug launches, signaling an exciting period for the company as it advances its epilepsy treatment pipeline. Dr. Von Seggern previously held a partner role at ClearView Healthcare Partners and brings a robust background in pharmaceuticals and strategic planning.